ArticleJTO clinical and research reports2020
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by
Article in JTO clinical and research reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer.Respiratory research · 2026Article
- MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.Targeted oncology · 2025Review
- A Phase II Study of Cabozantinib in Patients WithJTO clinical and research reports · 2025Article
- A novel mesenchymal epithelial transition (MET) inhibitor, CB538, relieves acquired resistance inTranslational cancer research · 2025Article
- Combining mechanistic quantitative systems pharmacology modeling and patient-derived organoid testing in MET-aberrant non-small cell lung cancer for high-throughput combination efficacy analysis and personalized treatment design.Frontiers in pharmacology · 2025Article
- Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.Journal of cancer research and clinical oncology · 2024Article
- Metastatic Non-Small Cell Lung Cancer Mimicking Metaplastic Breast Cancer: A Case Report.JCO precision oncology · 2024Article
- Joint DNA-RNA-based NGS for diagnosis and treatment of a rareFrontiers in immunology · 2024Article
- Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.Lung cancer (Amsterdam, Netherlands) · 2023Article
- Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.JTO clinical and research reports · 2023Article
- Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.Cancer discovery · 2023Article
- Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.Journal of hematology & oncology · 2022Article
- Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.Molecular cancer therapeutics · 2022Article
- Non-small-cell lung cancer: how to manageDrugs in context · 2022Review
- Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib.JTO clinical and research reports · 2021Article
- Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors forJTO clinical and research reports · 2021Article
- Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor.JTO clinical and research reports · 2021Article
- Lung Cancer withLung Cancer (Auckland, N.Z.) · 2021Review
- Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a MetastaticFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.